Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination

Lancet Glob Health. 2022 Jan;10(1):e33-e34. doi: 10.1016/S2214-109X(21)00545-3.

¹ Clinical Development, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Durham, NC, USA.
² Patient Safety, Chief Medical Office, R&D, AstraZeneca India, Bangalore, India.
³ Patient Safety, Chief Medical Office, R&D, AstraZeneca, Gaithersburg, MD, USA.
⁴ BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
⁵ BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
⁶ BioPharmaceuticals, AstraZeneca, Gaithersburg, MD, USA.
⁷ Patient Safety, Chief Medical Office, R&D, AstraZeneca, Gothenburg, Sweden.
⁸ Clinical Development, Late-stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Electronic address: prakash.bhuyan@astrazeneca.com.

No abstract available

Publication types